Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.23.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Organization And Summary Of Significant Accounting Policies [Line Items]      
Accumulated deficit $ (433,923)   $ (444,768)
Cash, cash equivalents, and marketable securities 41,700    
Restricted cash included in other assets $ 2,489 $ 2,668 $ 2,500
Restricted Cash and Cash Equivalents, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other assets Other assets Other assets
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Takeda Pharmaceuticals Inc      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 0.00% 30.00%  
Revenue | Concentration of Credit Risk and Other Risks and Uncertainties | Bristol Myers Squibb      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 92.00% 70.00%  
K2 Loan and Security Agreement      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Borrowings $ 35,000   $ 35,000
Maturity date Jun. 01, 2024